PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 166.76 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Penumbra Inc | PEN | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 1.92 | 1.16% | 166.76 | 168.25 | 165.66 | 165.66 | 164.84 | 17:59:47 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,743 | 587,918 | $ 167.13 | $ 98,256,548 | 464,928 | 107.50 - 185.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:29:41 | 9,427 | $ 166.76 | USD |
Penumbra Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 5.82B | 34.91M | $ 6.60M | 0.15 | 429.40 | 32.43M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 5.53M | $ - | 0.00% | -49.00 | 7.10% |
Penumbra News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/07/2019 | 17:15 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/07/2019 | 16:17 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/07/2019 | 16:05 | PR Newswire (US) | Penumbra, Inc. Reports Third Quarter 2019 Financial Results |
| 11/06/2019 | 16:53 | Business Wire | Penumbra Indigo® Aspiration System IDE Trial for Acute.. |
| 10/24/2019 | 19:50 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/17/2019 | 16:05 | PR Newswire (US) | Penumbra, Inc. Schedules Third Quarter 2019 Earnings Release.. |
| 10/15/2019 | 19:34 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 164.00 | 171.68 | 153.28 | 165.92 | 688,597 | 2.76 | 1.68% |
| 1 Month | 146.90 | 175.525 | 143.99 | 159.96 | 532,190 | 19.86 | 13.52% |
| 3 Months | 144.55 | 175.525 | 107.50 | 147.75 | 597,436 | 22.21 | 15.36% |
| 6 Months | 132.79 | 185.70 | 107.50 | 152.00 | 479,391 | 33.97 | 25.58% |
| 1 Year | 129.37 | 185.70 | 107.50 | 145.59 | 435,507 | 37.39 | 28.9% |
| 3 Years | 63.80 | 185.70 | 57.85 | 127.65 | 297,830 | 102.96 | 161.38% |
| 5 Years | 40.00 | 185.70 | 35.315 | 111.85 | 274,892 | 126.76 | 316.9% |
Penumbra Description
| Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for the neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. |
